Business Wire

NTT Com Wins Two MEF 3.0 Proof of Concept Awards

21.11.2019 09:03:00 EET | Business Wire | Press release

Share

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO: 9432), announced today it received MEF 3.0 Proof of Concept Awards in two categories, “MEF3.0 SD-WAN Implementation 2019” and “Network Slicing Implementation 2019,” during the MEF 3.0 Proof of Concept Showcase event held in the U.S. city of Los Angeles from November 18 to 22.

The showcase was organized by the Metro Ethernet Forum (MEF), a global telecom industry alliance with more than 220 members. NTT Com attended the showcase to introduce an SD-WAN1 service and a 5G-related proof of concept (PoC)2, joining other telecom carriers and manufacturers that presented their own initiatives for judging.

About MEF Awards
https://www.mef.net/2019_MEF_Awards

MEF3.0 SD-WAN Implementation 2019
NTT Com’s orchestrated virtualized multivendor SD-WAN services received the award presented for the best SD-WAN service in compliance with MEF specifications. The NTT Com service was recognized for enabling lifecycle3 management and operation of multiple SD-WAN products with a unified portal and white box CPEs4.

SD-WAN is not a standardized technology, so many unique network devices exist, requiring operation methods to be designed to each manufacturer’s technologies. To solve this problem, NTT Com conducted a PoC to implement unified control of multiple SD-WAN products based on MEF-standardized SD-WAN specifications, data models, interfaces and test methods.

NTT Com collaborated with partner companies to co-develop the orchestrated virtualized multivendor SD-WAN services in conformance with the MEF70 and MEF SD-WAN Presto API standard5. The service uses a universal CPE platform, enabling multiple SD-WAN products to be installed on the white box CPE, and a unified configuration portal, enabling unified control of multiple SD-WAN products.

The partner companies involved in co-development are ADVA, Netcracker Technology, Silver Peak, Spirent Communications, Versa Networks and NEC Corporation.

Network Slicing Implementation 2019
The award for the best network slicing6 technology was presented to NTT Com collaborating with partner companies for its 5G xHaul Sharing Slices with LSO Orchestration, which enables automatic control by using network slices for multiple-operator interconnection.

5G technology is anticipated to be used in companies and local governments in addition to telecom carriers by utilizing to such as private 5G service. The new network system that the various companies can use in common like this is necessary to build the network effectively.

NTT Com collaborated with partner companies to co-develop the shared xHaul architecture in conformance with the MEF standard by utilizing network slicing technology.
The architecture creates end-to-end network slices by multi-operator collaboration to share the access network (xHaul) required for 5G service.

The partner companies that contributed to the solution are NTT Corporation and Okinawa Open Laboratory.

SDN7 and network functions virtualization (NFV)8 technologies continue to be advanced through open-source development projects and by standardization organizations. Going forward, NTT Com aims to help drive the development of SDN and NFV technologies through its participation in MEF and ONF9.

1:

SD-WAN simplifies the management and operation of a WAN by separating the networking hardware from its control mechanism.

2:

Verification and demonstration of prototype development to demonstrate new concepts, theories, principles and ideas for commercialization and service development

3:

Service provision process covering application, start of use, settings and quality control

4:

Separates CPE hardware and software functions and allows software selection and installation for each application

5:

MEF specification for SD-WAN: https://www.mef.net/resources/technical-specifications/download?id=122&fileid=file1

6:

Virtual division of network according to characteristics, such as low latency, wide bandwidth or high reliability, by application purpose

7:

Technologies that dynamically control network configuration and settings using software

8:

Method for operating network devices as software on virtualized infrastructure of general-purpose servers

9:

Open Networking Foundation, which standardizes SDN technologies and develops open source software

Related links

About NTT Communications
NTT Communications solves the world's technology challenges by helping enterprises overcome complexity and risk in their ICT environments with managed IT infrastructure solutions. These solutions are backed by our worldwide infrastructure, including industry leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 450,000m2 of the world's most advanced data center facilities. Our global professional services teams provide consultation and architecture for the resiliency and security required for your business success, and our scale and global capabilities in technology world are unsurpassed. Combined with NTT Ltd., NTT Data, and NTT DOCOMO, we are NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information
Ryu Kanishima
Service Strategy Department
NTT Communications
Mail: mgr-nwcore-td@ntt.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye